Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL - European Medical Journal

Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL

Hematology
At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) study of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigator’s choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma (MCL).

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now